NImmune Biopharma

76 posts

NImmune Biopharma banner
NImmune Biopharma

NImmune Biopharma

@NImmuneBio

Pioneering Precision Immunology🧬 | Late-Stage Biopharma💊 | Biomarker-Driven Therapies🔬 | Computational Modeling & Bioinformatics📊 | Tackling UC & Crohn's

Blacksburg, VA Katılım Mart 2023
4 Takip Edilen6 Takipçiler
NImmune Biopharma retweetledi
The NIMML Institute
The NIMML Institute@NIMMLab·
At #IMMUNOLOGY2026, we presented new data showing that LANCL2 medicines reduced respiratory disease, lung lesions and inflammation and increased lung Tregs in mouse models of asthma. Read our recent article to learn more: linkedin.com/pulse/new-data…
The NIMML Institute tweet media
English
0
1
1
74
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Dr. Josep Bassaganya‑Riera is launching a clinical program advancing NIM‑1324 a next‑gen oral, once-daily LANCL2 therapeutic for IBD. NIM‑1324 targets both gut and extraintestinal disease through a systemic approach. Results will be presented at #DDW2026. businesswire.com/news/home/2026…
NImmune Biopharma tweet media
English
0
1
1
60
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
New research in @Nature Magazine Scientific Reports shows omilancor improves cognition and reduces Alzheimer’s symptoms. This reinforces the therapeutic potential of omilancor, our lead product candidate for inflammatory and autoimmune disease. Read more: nature.com/articles/s4159…
English
0
1
0
29
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Dr. Josep Bassaganya-Riera, our Founder & CEO, was featured on the Biotech Blueprint podcast, delving into the scientific underpinnings of how NImmune’s lead candidates outperform current IBD drugs in efficacy and safety. Listen here: open.spotify.com/show/6bn77qe68…
NImmune Biopharma tweet media
English
0
1
0
44
NImmune Biopharma retweetledi
The NIMML Institute
The NIMML Institute@NIMMLab·
We are excited to contribute to the 3rd edition of “Goals in Nutrition Science” (2025–2030), a forthcoming initiative from @FrontNutrition sharing global perspectives on the future of the field, incl. a section on immunometabolism from our founder Josep Bassaganya-Riera. (1/2)
The NIMML Institute tweet media
English
2
1
1
31
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
ICYMI: Eli Lilly and Nvidia recently announced a new partnership to leverage AI capabilities for drug discovery & development. At NImmune, we've successfully demonstrated how advanced AI models can greatly accelerate therapeutic discovery & development. nimmunebio.com/the-nimml-inst…
NImmune Biopharma tweet media
English
0
1
1
39
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Listen to our Founder & CEO, Dr. Josep Bassaganya-Riera, on the @BioWorld Insider podcast, where he discusses how NImmune is leveraging the TITAN-X AI platform to advance precision medicine in inflammatory and autoimmune diseases. Listen here: bioworld.com/media/podcasts…
NImmune Biopharma tweet media
English
0
2
3
186
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Today on #WorldIBDDay, we stand with the global IBD community in the fight against Crohn’s disease and ulcerative colitis. At NImmune, our team is advancing omilancor, a first-in-class oral therapeutic targeting LANCL2, now in Phase 3.
NImmune Biopharma tweet media
English
0
2
3
162
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Excited to share that our Founder & CEO, Dr. Josep Bassaganya-Riera is featured in a Q&A by CityBiz, discussing NImmune’s mission to advance our first-and best-in-class, biomarker-driven immunoregulatory therapeutics. Read it here: citybiz.co/article/695235…
NImmune Biopharma tweet media
English
0
0
0
29
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
New #DDW2025 data: once-daily oral omilancor outperformed anti-TL1A in IBD on efficacy & safety. Results show reversal of Treg depletion & mitochondrial dysfunction in UC. Best-in-class profile supports NDA path by 2027. Read more: businesswire.com/news/home/2025…
NImmune Biopharma tweet media
English
0
1
4
48
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Thrilled to share that our Founder & CEO, Dr. Josep Bassaganya-Riera, was featured on @LaunchBio’s NextGen VC podcast to discuss his journey building Landos Biopharma from new scientific findings to a $600M market cap company. Listen here: launchbio.org/nextgen-vc-pod…
NImmune Biopharma tweet media
English
0
2
3
62
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Thrilled to see @NIMMLab’s new #TITANX applications in @AnnualReviews. This #AI platform is driving our drug pipeline, from omilancor to NIM-1324, accelerating #PrecisionMedicine for #immunology. Keep innovating!
The NIMML Institute@NIMMLab

Excited to share new case studies in @AnnualReviews showing how our TITAN-X #AI platform fuels next-gen #immunology & #inflammation therapies. By unlocking novel targets like LANCL2, we’re advancing #PrecisionMedicine. Read the peer-reviewed article here: annualreviews.org/content/journa…

English
0
1
2
46
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Check out our Founder & CEO, Dr. Josep Bassaganya-Riera, on the Life Science & Biotech CEO Stories podcast as he shares his success story and how he's leading the charge in applying A.I. to biotech innovation. Listen here: biotechinsights.net/post/he-s-sett…
NImmune Biopharma tweet media
English
0
2
2
51
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
We are pleased to announce that new data from two IBD studies will be presented at @DDWMeeting. The studies focus on the best-in-class efficacy and safety profile, novel mechanism and combination therapies of omilancor & TL1A. Read more: #DDW2025" target="_blank" rel="nofollow noopener">businesswire.com/news/home/2025…
NImmune Biopharma tweet media
English
0
1
3
57
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
Excited to share publication of positive Phase 1 results for NIM-1324 in treating Systemic Lupus Erythematosus! This milestone highlights our commitment to precision medicine and addressing unmet needs in immune-mediated diseases. Kudos to @NIMMLab for the collaboration!
The NIMML Institute@NIMMLab

Our paper on Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, was accepted to the #CTSJournal! Findings validated NIM-1324 as a well-tolerated treatment for SLE. Read it in @ASCPTjournals: #ASCPTJournalFamily" target="_blank" rel="nofollow noopener">nimml.org/news/detail/th…

English
0
1
1
46
NImmune Biopharma
NImmune Biopharma@NImmuneBio·
We are pleased to share that NImmune will be attending #JPM2025 in San Francisco from January 13–16! We look forward to engaging in impactful conversations, connecting with industry leaders, and building our network to start 2025 on a strong note.
NImmune Biopharma tweet media
English
0
2
2
83

Keşfet

@Nature @BiotechnologyPa @FrontNutrition @BioWorld @LaunchBio @NIMMLab @AnnualReviews @FrontiersIn